Q2 2025 Earnings Call Transcript August 11, 2025 Kymera Therapeutics, Inc. misses on earnings expectations. Reported EPS is $ ...

Q2 2025 Management View CEO Nello Mainolfi outlined major progress in 2025, declaring “the updates we've shared in the first ...

Kymera Therapeutics Inc (KYMR) extends cash runway into 2028, bolstered by key partnerships with Gilead and Sanofi, despite ...

As for recent success stories from its biotech portfolio, Hatteras namechecked Kymera Therapeutics. The VC fund contributed ...

Second Quarter 2025 Results Key Financial Results Revenue: US$11.5m (down 55% ...

Phase 1 healthy volunteer data surpassing Kymera’s target product profile, and further validating its oral, dupilumab-like profile KT-621 BroADen Phase 1b trial in moderate to severe atopic dermatitis ...

Detailed price information for Kymera Therapeutics Inc (KYMR-Q) from The Globe and Mail including charting and trades.

Kymera Therapeutics belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, Denali Therapeutics Inc. (DNLI), has gained 13.3% over the past month.

Kymera is the only one of the four Protein Degraders mentioned above to be targeting dermatological conditions, which as discussed is a vast, and lucrative market in which AbbVie's Humira (>$19bn ...

The Kymera jet-powered body board has since been evolving into what's now a near production-ready machine complete with official specifications and pricing. We recently had some fun on the water ...